The effects of continuous prostacyclin infusion on regional blood flow and cerebral vasospasm following subarachnoid haemorrhage: study protocol for a randomised controlled trial

Rune Rasmussen, Jørn Wetterslev, Trine Stavngaard, Jane Skjøth-Rasmussen, Per Olof Grände, Niels Vidiendal Olsen, Bertil Romner, Rune Rasmussen, Jørn Wetterslev, Trine Stavngaard, Jane Skjøth-Rasmussen, Per Olof Grände, Niels Vidiendal Olsen, Bertil Romner

Abstract

Background: One of the main causes of mortality and morbidity following subarachnoid haemorrhage (SAH) is the development of cerebral vasospasm, a frequent complication arising in the weeks after the initial bleeding. Despite extensive research, to date no effective treatment of vasospasm exists. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation. In vitro models have shown a relaxing effect of prostacyclin after induced contraction in cerebral arteries, and a recent pilot trial showed a positive effect on cerebral vasospasm in a clinical setting. No randomised, clinical trials have been conducted, investigating the possible pharmacodynamic effects of prostacyclin on the human brain following SAH.

Methods: This trial is a single-centre, randomised, placebo-controlled, parallel group, blinded, clinical, pilot trial. A total of 90 patients with SAH will be randomised to one of three intervention arms: epoprostenol 1 ng/kg/min, epoprostenol 2 ng/kg/min or placebo in addition to standard treatment. Trial medication will start day 5 after SAH and continue to day 10. The primary outcome measure is changes in regional cerebral blood flow from baseline in the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery, measured by CT perfusion scan. The secondary outcomes will be vasospasm measured by CT angiography, ischaemic parameters measured by brain microdialysis, flow velocities in the medial cerebral artery, clinical parameters and outcome (Glasgow Outcome Scale) at 3 months.

Trial registration: Clinicaltrials.gov NCT01447095.

Figures

Figure 1
Figure 1
Flow diagram.

References

    1. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998;50(5):1413–1418. doi: 10.1212/WNL.50.5.1413.
    1. Dorsch NW. Cerebral arterial spasm–a clinical review. Br J Neurosurg. 1995;9(3):403–412. doi: 10.1080/02688699550041403.
    1. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YB. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–2395. doi: 10.1161/STROKEAHA.110.589275.
    1. Loch MR. Management of cerebral vasospasm. Neurosurg Rev. 2006;29(3):179–193. doi: 10.1007/s10143-005-0013-5.
    1. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy in aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(7):2186–2187. doi: 10.1161/STROKEAHA.107.509257.
    1. Hansen-Schwartz J. Cerebral vasospasm: a consideration of the various cellular mechanisms involved in the pathophysiology. Neurocrit Care. 2004;1(2):235–246. doi: 10.1385/NCC:1:2:235.
    1. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1(8001):18–20.
    1. Nosko M, Schulz R, Weir B, Cook DA, Grace M. Effects of vasospasm on levels of prostacyclin and thromboxane A2 in cerebral arteries of the monkey. Neurosurgery. 1988;22(1 Pt 1):45–50. doi: 10.1227/00006123-198801010-00007.
    1. Boullin DJ, Bunting S, Blaso WP, Hunt TM, Moncada S. Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol. 1979;7(2):139–147. doi: 10.1111/j.1365-2125.1979.tb00914.x.
    1. Brandt L, Ljunggren B, Andersson KE, Hindfelt B, Uski T. Effects of indomethacin and prostacyclin on isolated human pial arteries contracted by CSF from patients with aneurysmal SAH. J Neurosurg. 1981;55(6):877–883. doi: 10.3171/jns.1981.55.6.0877.
    1. Paul KS, Whalley ET, Forster C, Lye R, Dutton J. Prostacyclin and cerebral vessel relaxation. J Neurosurg. 1982;57(3):334–340. doi: 10.3171/jns.1982.57.3.0334.
    1. Bentzer P, Venturoli D, Carlsson O, Grande PO. Low-dose prostacyclin improves cortical perfusion following experimental brain injury in the rat. J Neurotrauma. 2003;20(5):447–461. doi: 10.1089/089771503765355522.
    1. Lundblad C, Grande PO, Bentzer P. Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin. J Cereb Blood Flow Metab. 2008;28(2):367–376. doi: 10.1038/sj.jcbfm.9600533.
    1. Grande PO, Lundgren A, Bjartmarz H, Cronqvist M. Segmental cerebral vasoconstriction: successful treatment of secondary cerebral ischaemia with intravenous prostacyclin. Cephalalgia. 2010;30(7):890–895. doi: 10.1177/0333102409352909.
    1. Grande PO, Moller AD, Nordstrom CH, Ungerstedt U. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiol Scand. 2000;44(7):886–894. doi: 10.1034/j.1399-6576.2000.440718.x.
    1. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26(8):1251–1262. doi: 10.1089/neu.2008.0605.
    1. Koskinen LO, Olivecrona M, Rodling-Wahlstrom M, Naredi S. Prostacyclin treatment normalises the MCA flow velocity in nimodipine-resistant cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study. Acta Neurochir (Wien) 2009;151(6):595–599. doi: 10.1007/s00701-009-0295-4.
    1. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123–1124. doi: 10.1136/bmj.323.7321.1123.
    1. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38(11):3055–3062. doi: 10.1161/STROKEAHA.107.488536.
    1. Moller AD, Grande PO. Beneficial effects of low-dose prostacyclin on cat intestinal perfusion during endotoxemia as evaluated with microdialysis and oxygen transport variables. Crit Care Med. 2001;29(2):351–358. doi: 10.1097/00003246-200102000-00025.
    1. Reinstrup P, Nordstrom CH. Prostacyclin infusion may prevent secondary damage in pericontusional brain tissue. Neurocrit Care. 2011;14(3):441–446. doi: 10.1007/s12028-010-9486-3.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever